USH1737H - 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same - Google Patents
7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same Download PDFInfo
- Publication number
- USH1737H USH1737H US08/828,460 US82846097A USH1737H US H1737 H USH1737 H US H1737H US 82846097 A US82846097 A US 82846097A US H1737 H USH1737 H US H1737H
- Authority
- US
- United States
- Prior art keywords
- compound
- alkyl
- arylalkyl
- cycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 38
- -1 7-oxabicycloheptane carboxylic acid prostaglandin Chemical class 0.000 title claims description 18
- 239000000543 intermediate Substances 0.000 title abstract description 26
- 238000002360 preparation method Methods 0.000 title description 4
- 230000002785 anti-thrombosis Effects 0.000 title description 2
- 239000003146 anticoagulant agent Substances 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 40
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 30
- 125000003118 aryl group Chemical group 0.000 claims abstract description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 13
- 238000005859 coupling reaction Methods 0.000 claims description 11
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 11
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 9
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 238000003379 elimination reaction Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 6
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 238000003436 Schotten-Baumann reaction Methods 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical group 0.000 claims description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 230000002140 halogenating effect Effects 0.000 claims description 4
- 150000003944 halohydrins Chemical class 0.000 claims description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 238000007363 ring formation reaction Methods 0.000 claims description 4
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims description 4
- 238000005576 amination reaction Methods 0.000 claims description 3
- 238000007112 amidation reaction Methods 0.000 claims description 2
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical compound OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 claims description 2
- FVIRGMIYFJWRGC-UHFFFAOYSA-N sulfurobromidic acid Chemical compound OS(Br)(=O)=O FVIRGMIYFJWRGC-UHFFFAOYSA-N 0.000 claims description 2
- FISBJBZERZFHPS-UHFFFAOYSA-N 2-cycloheptyloxepane-2-carboxylic acid Chemical compound C1CCCCCC1C1(C(=O)O)CCCCCO1 FISBJBZERZFHPS-UHFFFAOYSA-N 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- 239000002002 slurry Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 125000001475 halogen functional group Chemical group 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 5
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 5
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 238000006809 Jones oxidation reaction Methods 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000010973 in-process GC method Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 description 4
- DTIQPXGBDWZIGA-UHFFFAOYSA-N 2-amino-3,3-dimethoxy-n-pentylpropanamide Chemical compound CCCCCNC(=O)C(N)C(OC)OC DTIQPXGBDWZIGA-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 102000003938 Thromboxane Receptors Human genes 0.000 description 3
- 108090000300 Thromboxane Receptors Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 229910021204 NaH2 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 108010069102 Thromboxane-A synthase Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- RPUSRLKKXPQSGP-UHFFFAOYSA-N methyl 3-phenylpropanoate Chemical compound COC(=O)CCC1=CC=CC=C1 RPUSRLKKXPQSGP-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 150000002918 oxazolines Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AROOFDOMTBZSNZ-UHFFFAOYSA-N 2-bromo-3,3-dimethoxy-n-pentylpropanamide Chemical compound CCCCCNC(=O)C(Br)C(OC)OC AROOFDOMTBZSNZ-UHFFFAOYSA-N 0.000 description 1
- FNWXNZOHUAYOJI-UHFFFAOYSA-N 2-bromo-3,3-dimethoxypropanoic acid Chemical compound COC(OC)C(Br)C(O)=O FNWXNZOHUAYOJI-UHFFFAOYSA-N 0.000 description 1
- AZIIYWSJCGXMCO-UHFFFAOYSA-N 3,4,4a,5,6,7,8,8a-octahydro-2h-chromen-3-ol Chemical class C1CCCC2CC(O)COC21 AZIIYWSJCGXMCO-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 101100177155 Arabidopsis thaliana HAC1 gene Proteins 0.000 description 1
- ZNSMNVMLTJELDZ-UHFFFAOYSA-N Bis(2-chloroethyl)ether Chemical compound ClCCOCCCl ZNSMNVMLTJELDZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 229910003944 H3 PO4 Inorganic materials 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- 101100434170 Oryza sativa subsp. japonica ACR2.1 gene Proteins 0.000 description 1
- 101100434171 Oryza sativa subsp. japonica ACR2.2 gene Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- 229940099508 TP receptor antagonist Drugs 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 238000006840 aza-Achmatowicz rearrangement reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002455 vasospastic effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Definitions
- the present invention relates to novel 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates which may be used to prepare a final anti-thrombotic--anti-vasospastic product, and to methods for preparing same.
- U.S. Pat. No. 5,100,889 to Misra et al discloses 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs which are thromboxane A 2 (TXA 2 ) receptor antagonists or combined thromboxane A 2 receptor antagonist/thromboxane synthetase inhibitors useful, for example, in the treatment of thrombotic and/or vasospastic diseases, and have good duration of action.
- TXA 2 thromboxane A 2
- Examples of compounds disclosed in Misra et al have the structural formula I ##STR3## and including all stereoisomers thereof, wherein
- n 0, 1, 2, 3 or 4;
- R 1 is hydrogen, lower alkyl, aralkyl, aryl, cycloalkyl, cycloalkylalkyl, or amide ##STR4## wherein t is 1 to 12 and R a is lower alkyl, aryl, cycloalkyl, or cycloalkylalkyl);
- R 2 is hydrogen, lower alkyl, aryl, or aralkyl; or R 1 and R 2 together with the nitrogen to which they are linked may form a 5- to 8- membered ring.
- misra et al disclose that these compounds may be prepared by transmetallating bromophenylalkyl B ##STR5## by treatment with t-C 4 H 9 Li or n-C4H9Li or subjecting B to a Grignard reaction by treatment with Mg, and then condensing with the perhydro benzopyran-3-ol derivative or the perhydro benzofuran-1-ol derivative C ##STR6## to form the condensed 7-oxabicycloheptane alcohol compound of the structure Z ##STR7## and then subjecting the condensed compound to hydrogenolysis to form the following alcohol ##STR8## Where Pro is thexyldimethylsilyl or t-butyldimethylsilyl, the alcohol is acetylated and the silyl protecting group of the so-formed acetate is removed to form the following acetate: ##STR9## which is treated with a protecting compound and the acetate is removed by treatment with aqueous hydroxide or
- the so-formed carboxylic acid intermediate is then employed to make the final compound.
- Misra et al disclose protecting the alcohol function of alcohol Z to form the protected alcohol ##STR12## subjecting the protected alcohol to a Jones oxidation and esterification to form the ester ##STR13## which is made to undergo hydrogenolysis and subsequent removal of the acetate protecting group by transesterification to afford the alcohol ##STR14## which is subjected to a Jones oxidation to form the carboxylic acid intermediate II ##STR15##
- the above carboxylic acid intermediate II is formed by treating D' with acetic anhydride and removing the protecting group to form the acetate alcohol ##STR16## which is made to undergo a Dess-Martin oxidation to form the aldehyde ##STR17##
- the above aldehyde is oxidized and esterified to the corresponding acetate ester, deprotected, and subjected to a Jones oxidation to form carboxylic acid II where n is 1.
- U.S. Pat. No. 5,399,725 to Poss et al discloses a method for preparing an intermediate used in preparing compounds disclosed in U.S. Pat. No. 5,100,889 to Misra et al.
- an aldehyde ##STR18## is prepared and subjected to a Horner-Emmons reaction to form the ester of the structure ##STR19##
- the ester is hydrogenated to the carboxylic acid II described with respect to the Misra et al U.S. Pat. 5,100,889, which may be used in making the final anti-thrombotic--anti-vasospastic compounds as disclosed in U.S. Pat. No. 5,100,889 to Misra et al.
- one aspect of the present invention includes a method for preparing an amide intermediate of the structure IX ##STR21## (which is a novel compound)
- R is alkyl, aryl, arylalkyl or cycloalkyl
- R 1 is alkyl, arylalkyl or cycloalkyl.
- the hydrogenolysis of VIII preferably is carried out by treating VIII with hydrogen in the presence of an alcohol, such as methanol.
- the intermediate compound VIII is prepared by subjecting intermediate halo compound of the structure VII ##STR24## (which is a novel compound)
- R 2 is as defined above.
- intermediate halo compound VII ##STR25## is prepared by subjecting a compound of the structure ##STR26## to a halohydrin reaction by reacting IV with a halogenating agent such as a halosuccinimide or dibromodimethylhydantoin (DBDMH), preferably N-bromosuccinimide, in the presence of an alcohol IVA
- R 1 is as defined above, such as methanol or ethanol, preferably methanol, to form compound V ##STR27## (wherein R 1 is preferably alkyl) and subjecting compound V to an amidation reaction by reacting V with an amine of the structure VI
- a method for preparing intermediate compound of the structure XII ##STR28## wherein R and R 1 are as defined above, which includes the steps of reacting starting acid II preferably with Vilsmeier reagent in the presence of an inert organic solvent such as toluene, to form acid chloride XI, subjecting acid chloride XI ##STR29## and compound IX of the structure ##STR30## wherein R and R 1 are as defined above, to a coupling reaction, to form compound XII.
- the coupling reaction is a Schotten-Baumann coupling carried out in the presence of a weak base, such as sodium bicarbonate.
- a method for forming a thromboxane receptor antagonist of the structure XIV ##STR31## wherein R is as defined above, wherein compound XII is treated with a cyclizing agent, preferably trimethylsilyl trifluoromethane-sulfonate (TMSOTf) or chlorosulfonic acid, to form a mixture of four isomers XIII ##STR32## the mixture of isomers XIII is subject to an elimination reaction wherein XIII is treated with a base, preferably sodium methoxide or potassium t-butoxide/butanol, in the presence of an inert organic solvent, such as ethylene glycol dimethyl ether (also referred to as 1,2-dimethoxyethane or DME) or methyl acetate, to form thromboxane receptor antagonist XIV.
- a base preferably sodium methoxide or potassium t-butoxide/butanol
- an inert organic solvent such as ethylene glycol dimethyl
- product XIV may be prepared directly from XII by reacting XII with titanium tetrachloride/2,6-lutidine.
- novel intermediates having the following formulae: ##STR33## wherein R is alkyl, aryl, arylalkyl or cycloalkyl;
- R 1 is alkyl, arylalkyl or cycloalkyl
- R 5 is amino, halogen (Halo), preferably Br, R 2 --NH (where R 2 is aryl or arylalkyl), alkyl, aryl, arylalkyl or cycloalkyl.
- novel intermediates of the invention include the following type compounds: ##STR34##
- R 1 is alkyl such as methyl
- R 2 is arylalkyl such as benzyl
- R is alkyl such as n-pentyl.
- novel intermediates of the invention include compounds of the formula ##STR35## where R and R 1 are as defined above.
- R 1 is alkyl such as methyl, alkyl is methyl, and R is alkyl such as n-pentyl.
- the acrylate starting material IV is subjected to a halohydrin reaction with a halogenating agent such as halosuccinimide, such as N-bromosuccinimide, N-chlorosuccinimide or N-iodosuccinimide or dibromodimethylhydantoin (DBDMH), preferably N-bromosuccinimide, and an alcohol R 1 OH (IVA), for example, methanol, ethanol, or isopropanol, preferably methanol, at a temperature within the range from about 15° to about 35° C., preferably from about 20° to about 30° C., (to form propanoic acid V) employing a molar ratio of halogenating agent:IV within the range from about 0.5:1 to about 2:1, preferably from about 0.75:1 to about 1.25:1.
- a halogenating agent such as halosuccinimide, such as N-bromosuccinimide, N-chlorosuccinimi
- the resulting propanoic acid V is amidated by reacting V with amine VI (to form halo compound VII) under an inert atmosphere such as argon or nitrogen, preferably nitrogen, at a temperature within the range of from about 15° to about 35° C., preferably from about 20° to about 30° C., employing a molar ratio of amine VI:V within the range from about 0.75:1 to about 4:1, preferably from about 1:1 to about 2:1.
- an inert atmosphere such as argon or nitrogen, preferably nitrogen
- Halo compound VII is subjected to an amination reaction with amine VIA (to form amide VIII) under an inert atmosphere such as argon or nitrogen, preferably nitrogen, at an elevated temperature within the range from about 80° to about 140° C., preferably from about 90° to about 120° C., employing a molar ratio of amine VIA:VII with the range from about 0.75:1 to about 5:1, preferably from about 1:1 to about 4:1.
- an inert atmosphere such as argon or nitrogen, preferably nitrogen
- the intermediate amide IX is then formed by hydrogenolysis of amide VIII wherein VIII is dissolved in an inert organic solvent, such as an alcohol such as methanol, ethanol or isopropanol, tetrahydrofuran (THF), or DME, preferably methanol, and the resulting solution is treated with hydrogen in the presence of a hydrogenolysis catalyst, preferably Perlman catalyst (20% Pd(OH) 2 -50.8% H 2 O), although other catalysts such as palladium on carbon, platinum on carbon, may be employed.
- an inert organic solvent such as an alcohol such as methanol, ethanol or isopropanol, tetrahydrofuran (THF), or DME, preferably methanol
- a hydrogenolysis catalyst preferably Perlman catalyst (20% Pd(OH) 2 -50.8% H 2 O), although other catalysts such as palladium on carbon, platinum on carbon, may be employed.
- Amide IX is then converted to a salt IXA such as the corresponding oxalate, acetate or fumarate by treating a solution of amide IX in alcohol solvent such as methanol, ethanol or isopropanol, preferably methanol, with an acid such as oxalic acid, acetic acid or fumaric acid, preferably oxalic acid, at a temperature within the range from about 15° to about 35° C., preferably from about 20° to about 30° C., employing a molar ratio of acid:IX within the range from about 0.75:1 to about 3:1, preferably from about 1:1 to about 2:1, to form salt IXA, which is an intermediate for preparing thromboxane receptor antagonists.
- alcohol solvent such as methanol, ethanol or isopropanol, preferably methanol
- an acid such as oxalic acid, acetic acid or fumaric acid, preferably oxalic acid
- a temperature within the range from about
- the 7-oxabicycloheptane intermediate XII is prepared by subjecting acid II to acid chloride formation by treating acid II preferably with Vilsmeier reagent (chloromethylene)dimethyl ammonium chloride!, or other reagents such as oxalyl chloride, phosphorus pentachloride or thionyl chloride, in the presence of an inert organic solvent such as toluene, methylene chloride or diethyl ether, preferably toluene, under an inert atmosphere such as argon or nitrogen, preferably nitrogen, at a temperature within the range from about 15° to about 35° C., preferably from about 20° to about 30° C.
- Vilsmeier reagent chloromethylenedimethyl ammonium chloride!
- other reagents such as oxalyl chloride, phosphorus pentachloride or thionyl chloride
- an inert organic solvent such as toluene,
- the resulting acid chloride XI is made to undergo a coupling reaction, preferably a Schotten-Baumann coupling, with amide IXA to form 7-oxabicycloheptane intermediate XII.
- a coupling reaction preferably a Schotten-Baumann coupling
- acid chloride XI in an inert organic solvent such as ethyl acetate, methyl acetate, methylene chloride or diethyl ether, preferably ethyl acetate
- coupling agent which is a weak base such as an alkali metal bicarbonate, for example sodium bicarbonate, potassium bicarbonate or lithium bicarbonate, preferably sodium bicarbonate
- amide IXA at a temperature within the range from about -15° to about 20° C., preferably from about -10° to about 15° C., employing a molar ratio of IXA:XI within the range from about 0.75:1 to about 3:1, preferably from about 1:1 to about 2:1
- Intermediate XII may also be prepared employing other coupling reactions, for example, reacting acid chloride XI and amide IXA employing coupling reagents such as an organic base like piperidine, triethylamine, or diisopropylethylamine, at a temperature within the range from about -70° to about -55° C., preferably -78° C.
- coupling reagents such as an organic base like piperidine, triethylamine, or diisopropylethylamine
- thromboxane A 2 receptor antagonist XIV is prepared by subjecting compound XII to a cyclization reaction, preferably an Aza-Achmatowicz reaction wherein compound XII is dispersed in a reagent or solvent such as 1,2-dimethoxyethane (DME), methyl acetate or methylene chloride, preferably DME, under an inert atmosphere such as argon or nitrogen, preferably nitrogen, and is reacted with a cyclizing agent, such as trifluoromethanesulfonate (TMSOTf), or a halosulfonic acid like bromosulfonic acid, chlorosulfonic acid or fluorosulfonic acid, preferably TMSOTf or chlorosulfonic acid.
- a cyclization reaction preferably an Aza-Achmatowicz reaction wherein compound XII is dispersed in a reagent or solvent such as 1,2-dimethoxyethane (DME), methyl acetate or
- the reaction will be carried out at a temperature within the range from about 15° to about 50° C., preferably from about 20° to about 40° C.
- a halosulfonic acid is employed as the cyclizing agent
- the reaction will be carried out at a reduced temperature within the range from about -10° to about 10° C., preferably from about 0° to about 10° C.
- the molar ratio of cyclizing agent:XII employed will be within the range from about 0.75:1 to about 4:1, preferably from about 1:1 to about 3:1.
- a mixture of four isomers XIII is obtained which is made to undergo an elimination reaction wherein XIII is reacted with an organic base such as an alkali metal alkoxide, such as sodium methoxide, potassium t-butoxide/butanol, lithium t-butoxide, lithium methoxide, preferably sodium methoxide or potassium t-butoxide/butanol, in the presence of an inert organic solvent such as ethylene glycol dimethyl ether (DME), methyl acetate, methylene chloride, preferably DME, at a temperature within the range from about -20° to about 10° C., preferably from about -5° to about 5° C. to form XIV.
- an organic base such as an alkali metal alkoxide, such as sodium methoxide, potassium t-butoxide/butanol, lithium t-butoxide, lithium methoxide, preferably sodium methoxide or potassium t-butoxide/butanol
- the organic base will be employed in a molar ratio to XIII within the range from about 1:1 to about 7:1, preferably from about 2.1:1 to about 6:1.
- the cyclization-elimination sequence may also be carried out directly from XII in a one pot procedure by reacting XII with titanium tetrachloride/2,6-lutidine in a 1:2 molar ratio, at a temperature within the range from about 15° to about 45° C., preferably from about 20° to about 40° C., in the presence of an inert organic solvent such as methylene chloride or dichloroether, preferably methylene chloride, employing a molar ratio of titanium tetrachloride:XII within the range from about 2:1 to about 6:1, preferably from about 3:1 to about 5:1.
- an inert organic solvent such as methylene chloride or dichloroether, preferably methylene chloride
- the so-formed thromboxane A 2 receptor antagonist XIV may then be hydrolyzed to a corresponding salt employing conventional techniques such as treatment with an aqueous solution of an alkali metal base and then aqueous acid to form the corresponding acid which may be treated with sodium methoxide, sodium 2-ethyl-hexanoate or sodium ethoxide to form corresponding salt in the presence of acetone/methanol.
- lower alkyl or "alkyl” as employed herein includes both straight and branched chain radicals of up to 18 carbons, preferably 1 to 8 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1, 2 or 3 substituents such as halo, alkenyl, alkynyl, aryl, alkyl-aryl, haloaryl, cycloalkyl, or alkylcycloalkyl.
- substituents such as halo, alkenyl, alkynyl, aryl,
- cycloalkyl includes saturated cyclic hydrocarbon groups containing 3 to 12 carbons, preferably 3 to 8 carbons, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, any of which groups may be substituted with substituents such as halogen, lower alkyl, and/or alkoxy groups.
- aryl or “Ar” as employed herein refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, such as phenyl or naphthyl.
- Aryl (or Ar), phenyl or naphthyl may include substituted aryl, substituted phenyl or substituted naphthyl, which may include 1 or 2 substituents on either the phenyl or naphthyl such as lower alkyl, trifluoromethyl, halogen (Cl, Br, I or F), alkylsulfonyl, and/or arylsulfonyl.
- aralkyl refers to lower alkyl groups as discussed above having an aryl substituent, such as benzyl.
- lower alkoxy includes any of the above lower alkyl, alkyl or aralkyl groups linked to an oxygen atom.
- halogen or halo as used herein refers to Cl, Br, F or I, with Cl preferred.
- the final compounds XIV and esters and salts thereof prepared by the method of this invention are thromboxane receptor antagonists and as such are useful as inhibitors of thromboxane receptor mediated actions.
- thromboxane receptor antagonist includes compounds which are so-called thromboxane A 2 receptor antagonists, thromboxane A 2 antagonists, thromboxane A 2 /prostaglandin endoperoxide antagonists, TP-receptor antagonists, or thromboxane antagonists.
- the compounds prepared by the method of the invention are also thromboxane synthetase inhibitors and thus are useful as inhibitors of thromboxane production.
- N-bromo-succinimide (16.7 g, 1.1 equiv.) was slurried in MeOH (150 mL). The slurry was cooled to 0° to 5° C. and methyl-transmethoxyacrylate (10 g, 86.9 mmol) was added drop-wise over about 15 min. The reaction mixture became homogeneous about halfway into addition. The reaction mixture was warmed to ambient temperature and stirred until the GC area % ratio of input to output was ⁇ 0.5 as judged by an in-process GC method 1 . The reaction mixture was worked up after 16 hours.
- the reaction mixture was concentrated at ⁇ 40° C. under vacuum to ⁇ 40 mL.
- the concentrated reaction mixture was diluted with EtOAc ( ⁇ 140 mL).
- the solution was successively washed with 1N NaHCO 3 (3 ⁇ 50 mL) and 3% (w/v) aqueous NaCl solution and the rich organic layer was concentrated to afford title compound as a clear liquid (19.6 g, ⁇ 99M % as is).
- Example 1 compound (11.0 g, 48.6 mmol) was added neat n-amyl amine (11.83 mL, 102.1 mmol, 2.1 equiv.) under nitrogen at 0° to 5° C.
- the reaction mixture was warmed to ambient temperature and stirred until the GC area % ratio of input to output was ⁇ 0.5 by the in-process GC method described in Example 1.
- the reaction was worked up after ⁇ 16 hours.
- reaction mixture was diluted with tert-butylmethyl ether (MTBE) ( ⁇ 150 mL) and was extracted successively with 1M aqueous NaH 2 PO 4 (3 ⁇ 50 mL, pH 5 buffer) and 3% (w/v) aqueous NaCl solution (30 mL).
- MTBE tert-butylmethyl ether
- the rich washed organic layer was concentrated to ⁇ 50 mL at ⁇ 40° C. under vacuum ( ⁇ 25" of Hg) and heptane ( ⁇ 100 mL) was added. The remaining MTBE was exchanged for heptane under vacuum and more heptane was added to a final volume of ⁇ 150 mL ( ⁇ 14 mL/g input).
- the heptane solution was cooled from 35° C. to ambient temperature to initiate crystallization of the product.
- the crystal slurry was stirred at ambient temperature for several hours.
- the crystal slurry was filtered, washed with cold ( ⁇ 50° C.) heptane and dried under vacuum at ambient temperature to afford title compound as a white crystalline solid (10.5 g, ⁇ 78M % as is).
- Example 2 compound (4.0 g, 14.2 mmol) was added neat benzyl amine (4.65 mL, 42.6 mmol, 3 equiv.) under nitrogen and the reaction mixture was heated at 100° C. to 110° C. until the GC area % ratio of input to output was ⁇ 0.5 by the in-process GC method described in Example 1. The reaction mixture was worked up after 16 hours.
- reaction mixture was diluted with MTBE ( ⁇ 80 mL) and was extracted successively with Dl water (3 ⁇ 40 mL), 1M aqueous NaH 2 PO4 (40 mL, pH 5 buffer) and 3% (w/v) aqueous NaCl solution (40 mL).
- Example 3 compound (37.5 g, 121.6 mmol) was dissolved in methanol (150 mL) and the solution was transferred into a Buchi hydrogenator. The apparatus was purged with nitrogen. About 5.3 g of Perlman catalyst 20% Pd(OH) 2 -50.8% H 2 O! were added and the apparatus was purged with hydrogen. The hydrogenolysis was conducted at 40° C. (jacket temperature) and at 25 psi pressure of hydrogen. The progress of the reaction was followed by the in-process GC method described in Example 1. The reaction was judged to be complete when the GC area % ratio of input to output was ⁇ 0.1. The hydrogenolysis was stopped after four hours by purging the apparatus with nitrogen.
- reaction mixture was filtered to remove the catalyst.
- the catalyst was rinsed with MeOH ( ⁇ 2 ⁇ 20 mL).
- the methanolic solution containing title compound (theoretical yield ⁇ 26.5 g) was concentrated under vacuum at ⁇ 40° C. to a volume of ⁇ 60 mL (range 2 to 2.5 mL solution per gram of theoretical output of title compound).
- Solid oxalic acid•2 H 2 O (16.8 g, 133.7 mmol, 1.1 equiv.) was added to the Part A methanolic solution at ambient temperature and the agitation was continued to dissolve the acid.
- the reaction mixture was heated to 45°-50° C. to achieve two clear phases.
- the lower spent aqueous phase was separated and the upper rich organic phase was washed with 1 N aqueous NaHCO 3 (60 mL) followed by Dl water (2 ⁇ 60 mL).
- the temperature was maintained at 45°-50° C. to prevent the product from crystallizing out.
- Solvent B 40% Dl water+60% CH 3 CN
- Example 5 compound (20.72 g, 40 mmol) was slurried in 1,2-dimethoxyethane (280 mL) under N 2 and heated to 38° C. Trimethylsilyl trifluoromethane-sulfonate (TMSOTf) (11.5 mL, 60 mmol; 1.5 equiv.) was added. The solid quickly dissolved and the reaction was stirred until done by HPLC (used 2 additional charges of TMSOTf totalling 1.6 mL, 8 mmol), typically 2 h. A mixture of four oxazolines was obtained. The reaction mixture was cooled to -13° C. and a solution of 25 wt.
- TMSOTf Trimethylsilyl trifluoromethane-sulfonate
- Example 5 compound (15 g, 28.92 mmol) was slurried in anhydrous methyl acetate under N 2 and cooled to 0C. Chlorosulfonic acid (4.04 ml, 60.78 mmol, 2.1 eq.) was added. The solid quickly dissolved and the reaction was stirred for 2 h. A mixture of four oxazolines was obtained. This colorless solution was added dropwise by cannulation over 55 min. to a 0° C. solution of 1M potassium t-butoxide/t-butanol (144.6 ml, 144.6 mmol, 5.0 eq.) and anhydrous methyl acetate (52.5 ml). The reaction was done by the end of the addition.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method is provided for preparing intermediates for 7-oxabicycloheptane carboxylic acid intermediates of the structures <IMAGE> <IMAGE> wherein R is alkyl, aryl, arylalkyl or cycloalkyl; R1 is alkyl, arylalkyl or cycloalkyl; R2 is aryl or arylalkyl; and of the structure <IMAGE> where R and R1 are as defined above, which may be used in making the final anti-thrombotic-anti-vasospastic compounds.
Description
The present invention relates to novel 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates which may be used to prepare a final anti-thrombotic--anti-vasospastic product, and to methods for preparing same.
U.S. Pat. No. 5,100,889 to Misra et al discloses 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs which are thromboxane A2 (TXA2) receptor antagonists or combined thromboxane A2 receptor antagonist/thromboxane synthetase inhibitors useful, for example, in the treatment of thrombotic and/or vasospastic diseases, and have good duration of action. Examples of compounds disclosed in Misra et al have the structural formula I ##STR3## and including all stereoisomers thereof, wherein
m is 1, 2 or 3; n is 0, 1, 2, 3 or 4;
R1 is hydrogen, lower alkyl, aralkyl, aryl, cycloalkyl, cycloalkylalkyl, or amide ##STR4## wherein t is 1 to 12 and Ra is lower alkyl, aryl, cycloalkyl, or cycloalkylalkyl);
R2 is hydrogen, lower alkyl, aryl, or aralkyl; or R1 and R2 together with the nitrogen to which they are linked may form a 5- to 8- membered ring.
Misra et al disclose that these compounds may be prepared by transmetallating bromophenylalkyl B ##STR5## by treatment with t-C4 H9 Li or n-C4H9Li or subjecting B to a Grignard reaction by treatment with Mg, and then condensing with the perhydro benzopyran-3-ol derivative or the perhydro benzofuran-1-ol derivative C ##STR6## to form the condensed 7-oxabicycloheptane alcohol compound of the structure Z ##STR7## and then subjecting the condensed compound to hydrogenolysis to form the following alcohol ##STR8## Where Pro is thexyldimethylsilyl or t-butyldimethylsilyl, the alcohol is acetylated and the silyl protecting group of the so-formed acetate is removed to form the following acetate: ##STR9## which is treated with a protecting compound and the acetate is removed by treatment with aqueous hydroxide or excess methyllithium to form the following alcohol: ##STR10## (where Pro is t-butyldiphenylsilyl). The protected alcohol is subjected to a Jones oxidation to form the following acid: ##STR11##
The so-formed carboxylic acid intermediate is then employed to make the final compound.
In a more preferred procedure, Misra et al disclose protecting the alcohol function of alcohol Z to form the protected alcohol ##STR12## subjecting the protected alcohol to a Jones oxidation and esterification to form the ester ##STR13## which is made to undergo hydrogenolysis and subsequent removal of the acetate protecting group by transesterification to afford the alcohol ##STR14## which is subjected to a Jones oxidation to form the carboxylic acid intermediate II ##STR15##
In an alternative procedure where n is 1, the above carboxylic acid intermediate II is formed by treating D' with acetic anhydride and removing the protecting group to form the acetate alcohol ##STR16## which is made to undergo a Dess-Martin oxidation to form the aldehyde ##STR17## The above aldehyde is oxidized and esterified to the corresponding acetate ester, deprotected, and subjected to a Jones oxidation to form carboxylic acid II where n is 1.
U.S. Pat. No. 5,399,725 to Poss et al discloses a method for preparing an intermediate used in preparing compounds disclosed in U.S. Pat. No. 5,100,889 to Misra et al. In the Poss et al patent, an aldehyde ##STR18## is prepared and subjected to a Horner-Emmons reaction to form the ester of the structure ##STR19## The ester is hydrogenated to the carboxylic acid II described with respect to the Misra et al U.S. Pat. 5,100,889, which may be used in making the final anti-thrombotic--anti-vasospastic compounds as disclosed in U.S. Pat. No. 5,100,889 to Misra et al.
In accordance with the present invention, methods are provided for preparing intermediates for use in the preparation of 7-oxabicycloheptyl substituted oxazole amide prostaglandin analogs as described hereinafter which are useful as anti-thrombotic and anti-vasospastic compounds.
The methods of the invention are outlined in Reaction Schemes I to III set out hereinafter. ##STR20##
Referring to the above Reaction Schemes, as seen in Reaction Scheme I, one aspect of the present invention includes a method for preparing an amide intermediate of the structure IX ##STR21## (which is a novel compound)
wherein R is alkyl, aryl, arylalkyl or cycloalkyl; and
R1 is alkyl, arylalkyl or cycloalkyl.
As shown in Scheme I, in accordance with the present invention, a method is provided for preparing intermediate amide IX from intermediate amide compound of the structure VIII ##STR22## (which is a novel compound)
wherein R2 is aryl or arylalkyl, and R1 and R are as defined above, by subjecting amide compound VIII to hydrogenolysis to form amide IX ##STR23##
The hydrogenolysis of VIII preferably is carried out by treating VIII with hydrogen in the presence of an alcohol, such as methanol.
In addition, as seen in Scheme I, in accordance with the present invention, the intermediate compound VIII is prepared by subjecting intermediate halo compound of the structure VII ##STR24## (which is a novel compound)
wherein R and R1 are as defined above, to an amination reaction by reacting VII with an amine of the structure
VIA R.sup.2 --NH.sub.2
wherein R2 is as defined above.
In another aspect of the invention, as seen in Scheme I, intermediate halo compound VII ##STR25## is prepared by subjecting a compound of the structure ##STR26## to a halohydrin reaction by reacting IV with a halogenating agent such as a halosuccinimide or dibromodimethylhydantoin (DBDMH), preferably N-bromosuccinimide, in the presence of an alcohol IVA
(IVA) R.sup.1 OH
wherein R1 is as defined above, such as methanol or ethanol, preferably methanol, to form compound V ##STR27## (wherein R1 is preferably alkyl) and subjecting compound V to an amidation reaction by reacting V with an amine of the structure VI
VI H.sub.2 N--R
(wherein R is as defined above) to form compound VII.
In yet another aspect of the present invention, referring to Reaction Scheme II, a method is provided for preparing intermediate compound of the structure XII ##STR28## wherein R and R1 are as defined above, which includes the steps of reacting starting acid II preferably with Vilsmeier reagent in the presence of an inert organic solvent such as toluene, to form acid chloride XI, subjecting acid chloride XI ##STR29## and compound IX of the structure ##STR30## wherein R and R1 are as defined above, to a coupling reaction, to form compound XII.
In a preferred embodiment of the invention, the coupling reaction is a Schotten-Baumann coupling carried out in the presence of a weak base, such as sodium bicarbonate.
Referring to Reaction Scheme III, in accordance with the present invention, a method is provided for forming a thromboxane receptor antagonist of the structure XIV ##STR31## wherein R is as defined above, wherein compound XII is treated with a cyclizing agent, preferably trimethylsilyl trifluoromethane-sulfonate (TMSOTf) or chlorosulfonic acid, to form a mixture of four isomers XIII ##STR32## the mixture of isomers XIII is subject to an elimination reaction wherein XIII is treated with a base, preferably sodium methoxide or potassium t-butoxide/butanol, in the presence of an inert organic solvent, such as ethylene glycol dimethyl ether (also referred to as 1,2-dimethoxyethane or DME) or methyl acetate, to form thromboxane receptor antagonist XIV.
Alternatively product XIV may be prepared directly from XII by reacting XII with titanium tetrachloride/2,6-lutidine.
In addition, in accordance with the present invention, novel intermediates are provided having the following formulae: ##STR33## wherein R is alkyl, aryl, arylalkyl or cycloalkyl;
R1 is alkyl, arylalkyl or cycloalkyl;
R5 is amino, halogen (Halo), preferably Br, R2 --NH (where R2 is aryl or arylalkyl), alkyl, aryl, arylalkyl or cycloalkyl.
Thus the novel intermediates of the invention include the following type compounds: ##STR34##
It is preferred that R1 is alkyl such as methyl, R2 is arylalkyl such as benzyl, and R is alkyl such as n-pentyl.
In addition, novel intermediates of the invention include compounds of the formula ##STR35## where R and R1 are as defined above.
It is preferred that R1 is alkyl such as methyl, alkyl is methyl, and R is alkyl such as n-pentyl.
In carrying out the method of the invention as outlined in Reaction Scheme I for preparing intermediate IX, the acrylate starting material IV is subjected to a halohydrin reaction with a halogenating agent such as halosuccinimide, such as N-bromosuccinimide, N-chlorosuccinimide or N-iodosuccinimide or dibromodimethylhydantoin (DBDMH), preferably N-bromosuccinimide, and an alcohol R1 OH (IVA), for example, methanol, ethanol, or isopropanol, preferably methanol, at a temperature within the range from about 15° to about 35° C., preferably from about 20° to about 30° C., (to form propanoic acid V) employing a molar ratio of halogenating agent:IV within the range from about 0.5:1 to about 2:1, preferably from about 0.75:1 to about 1.25:1.
The resulting propanoic acid V is amidated by reacting V with amine VI (to form halo compound VII) under an inert atmosphere such as argon or nitrogen, preferably nitrogen, at a temperature within the range of from about 15° to about 35° C., preferably from about 20° to about 30° C., employing a molar ratio of amine VI:V within the range from about 0.75:1 to about 4:1, preferably from about 1:1 to about 2:1.
Halo compound VII is subjected to an amination reaction with amine VIA (to form amide VIII) under an inert atmosphere such as argon or nitrogen, preferably nitrogen, at an elevated temperature within the range from about 80° to about 140° C., preferably from about 90° to about 120° C., employing a molar ratio of amine VIA:VII with the range from about 0.75:1 to about 5:1, preferably from about 1:1 to about 4:1.
The intermediate amide IX is then formed by hydrogenolysis of amide VIII wherein VIII is dissolved in an inert organic solvent, such as an alcohol such as methanol, ethanol or isopropanol, tetrahydrofuran (THF), or DME, preferably methanol, and the resulting solution is treated with hydrogen in the presence of a hydrogenolysis catalyst, preferably Perlman catalyst (20% Pd(OH)2 -50.8% H2 O), although other catalysts such as palladium on carbon, platinum on carbon, may be employed.
Amide IX is then converted to a salt IXA such as the corresponding oxalate, acetate or fumarate by treating a solution of amide IX in alcohol solvent such as methanol, ethanol or isopropanol, preferably methanol, with an acid such as oxalic acid, acetic acid or fumaric acid, preferably oxalic acid, at a temperature within the range from about 15° to about 35° C., preferably from about 20° to about 30° C., employing a molar ratio of acid:IX within the range from about 0.75:1 to about 3:1, preferably from about 1:1 to about 2:1, to form salt IXA, which is an intermediate for preparing thromboxane receptor antagonists.
Referring to Reaction Scheme II, the 7-oxabicycloheptane intermediate XII is prepared by subjecting acid II to acid chloride formation by treating acid II preferably with Vilsmeier reagent (chloromethylene)dimethyl ammonium chloride!, or other reagents such as oxalyl chloride, phosphorus pentachloride or thionyl chloride, in the presence of an inert organic solvent such as toluene, methylene chloride or diethyl ether, preferably toluene, under an inert atmosphere such as argon or nitrogen, preferably nitrogen, at a temperature within the range from about 15° to about 35° C., preferably from about 20° to about 30° C.
The resulting acid chloride XI is made to undergo a coupling reaction, preferably a Schotten-Baumann coupling, with amide IXA to form 7-oxabicycloheptane intermediate XII. In carrying out the Schotten-Baumann coupling reaction, acid chloride XI, in an inert organic solvent such as ethyl acetate, methyl acetate, methylene chloride or diethyl ether, preferably ethyl acetate, and coupling agent which is a weak base such as an alkali metal bicarbonate, for example sodium bicarbonate, potassium bicarbonate or lithium bicarbonate, preferably sodium bicarbonate, are reacted with amide IXA, at a temperature within the range from about -15° to about 20° C., preferably from about -10° to about 15° C., employing a molar ratio of IXA:XI within the range from about 0.75:1 to about 3:1, preferably from about 1:1 to about 2:1, and a molar ratio of coupling agent:XI within the range from about 2:1 to about 8:1 preferably from about 3:1 to about 6:1.
Intermediate XII may also be prepared employing other coupling reactions, for example, reacting acid chloride XI and amide IXA employing coupling reagents such as an organic base like piperidine, triethylamine, or diisopropylethylamine, at a temperature within the range from about -70° to about -55° C., preferably -78° C. Molar ratios of coupling agent:XI will be as described above in the Schotten-Baumann coupling.
The resulting 7-oxabicycloheptane intermediate XII is employed to form thromboxane A2 receptor antagonist XIV.
Referring to Reaction Scheme III, thromboxane A2 receptor antagonist XIV is prepared by subjecting compound XII to a cyclization reaction, preferably an Aza-Achmatowicz reaction wherein compound XII is dispersed in a reagent or solvent such as 1,2-dimethoxyethane (DME), methyl acetate or methylene chloride, preferably DME, under an inert atmosphere such as argon or nitrogen, preferably nitrogen, and is reacted with a cyclizing agent, such as trifluoromethanesulfonate (TMSOTf), or a halosulfonic acid like bromosulfonic acid, chlorosulfonic acid or fluorosulfonic acid, preferably TMSOTf or chlorosulfonic acid. Where TMSOTf is employed as the cyclizing agent, the reaction will be carried out at a temperature within the range from about 15° to about 50° C., preferably from about 20° to about 40° C. Where a halosulfonic acid is employed as the cyclizing agent, the reaction will be carried out at a reduced temperature within the range from about -10° to about 10° C., preferably from about 0° to about 10° C. The molar ratio of cyclizing agent:XII employed will be within the range from about 0.75:1 to about 4:1, preferably from about 1:1 to about 3:1.
A mixture of four isomers XIII is obtained which is made to undergo an elimination reaction wherein XIII is reacted with an organic base such as an alkali metal alkoxide, such as sodium methoxide, potassium t-butoxide/butanol, lithium t-butoxide, lithium methoxide, preferably sodium methoxide or potassium t-butoxide/butanol, in the presence of an inert organic solvent such as ethylene glycol dimethyl ether (DME), methyl acetate, methylene chloride, preferably DME, at a temperature within the range from about -20° to about 10° C., preferably from about -5° to about 5° C. to form XIV.
In carrying out the elimination reaction, the organic base will be employed in a molar ratio to XIII within the range from about 1:1 to about 7:1, preferably from about 2.1:1 to about 6:1.
The above cyclization-elimination reaction is effected in a one-pot procedure. Furthermore, in compound XII, the carbon bearing an acetal has the same oxidation state as the oxazole in product XIV.
The cyclization-elimination sequence may also be carried out directly from XII in a one pot procedure by reacting XII with titanium tetrachloride/2,6-lutidine in a 1:2 molar ratio, at a temperature within the range from about 15° to about 45° C., preferably from about 20° to about 40° C., in the presence of an inert organic solvent such as methylene chloride or dichloroether, preferably methylene chloride, employing a molar ratio of titanium tetrachloride:XII within the range from about 2:1 to about 6:1, preferably from about 3:1 to about 5:1.
The so-formed thromboxane A2 receptor antagonist XIV may then be hydrolyzed to a corresponding salt employing conventional techniques such as treatment with an aqueous solution of an alkali metal base and then aqueous acid to form the corresponding acid which may be treated with sodium methoxide, sodium 2-ethyl-hexanoate or sodium ethoxide to form corresponding salt in the presence of acetone/methanol.
The term "lower alkyl" or "alkyl" as employed herein includes both straight and branched chain radicals of up to 18 carbons, preferably 1 to 8 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1, 2 or 3 substituents such as halo, alkenyl, alkynyl, aryl, alkyl-aryl, haloaryl, cycloalkyl, or alkylcycloalkyl.
The term "cycloalkyl" includes saturated cyclic hydrocarbon groups containing 3 to 12 carbons, preferably 3 to 8 carbons, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, any of which groups may be substituted with substituents such as halogen, lower alkyl, and/or alkoxy groups.
The term "aryl" or "Ar" as employed herein refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, such as phenyl or naphthyl. Aryl (or Ar), phenyl or naphthyl may include substituted aryl, substituted phenyl or substituted naphthyl, which may include 1 or 2 substituents on either the phenyl or naphthyl such as lower alkyl, trifluoromethyl, halogen (Cl, Br, I or F), alkylsulfonyl, and/or arylsulfonyl.
The term "aralkyl", "aryl-alkyl" or "aryl-lower alkyl" as used herein refers to lower alkyl groups as discussed above having an aryl substituent, such as benzyl.
The term "lower alkoxy", "alkoxy" or "aralkoxy" includes any of the above lower alkyl, alkyl or aralkyl groups linked to an oxygen atom.
The term "halogen" or "halo" as used herein refers to Cl, Br, F or I, with Cl preferred.
The final compounds XIV and esters and salts thereof prepared by the method of this invention are thromboxane receptor antagonists and as such are useful as inhibitors of thromboxane receptor mediated actions. The term "thromboxane receptor antagonist" includes compounds which are so-called thromboxane A2 receptor antagonists, thromboxane A2 antagonists, thromboxane A2 /prostaglandin endoperoxide antagonists, TP-receptor antagonists, or thromboxane antagonists.
The compounds prepared by the method of the invention are also thromboxane synthetase inhibitors and thus are useful as inhibitors of thromboxane production.
Examples of various utilities of the compounds prepared by the method of the invention are set out in U.S. Pat. No. 5,100,889.
The following Examples represent preferred embodiments of the present invention. Unless otherwise indicated, all temperatures are expressed in degrees Centigrade.
With protection from direct light, N-bromo-succinimide (16.7 g, 1.1 equiv.) was slurried in MeOH (150 mL). The slurry was cooled to 0° to 5° C. and methyl-transmethoxyacrylate (10 g, 86.9 mmol) was added drop-wise over about 15 min. The reaction mixture became homogeneous about halfway into addition. The reaction mixture was warmed to ambient temperature and stirred until the GC area % ratio of input to output was <0.5 as judged by an in-process GC method1. The reaction mixture was worked up after 16 hours.
The reaction mixture was concentrated at <40° C. under vacuum to ˜40 mL. The concentrated reaction mixture was diluted with EtOAc (˜140 mL). The solution was successively washed with 1N NaHCO3 (3×50 mL) and 3% (w/v) aqueous NaCl solution and the rich organic layer was concentrated to afford title compound as a clear liquid (19.6 g, ˜99M % as is).
To neat Example 1 compound (11.0 g, 48.6 mmol) was added neat n-amyl amine (11.83 mL, 102.1 mmol, 2.1 equiv.) under nitrogen at 0° to 5° C. The reaction mixture was warmed to ambient temperature and stirred until the GC area % ratio of input to output was <0.5 by the in-process GC method described in Example 1. The reaction was worked up after ˜16 hours.
The reaction mixture was diluted with tert-butylmethyl ether (MTBE) (˜150 mL) and was extracted successively with 1M aqueous NaH2 PO4 (3×50 mL, pH 5 buffer) and 3% (w/v) aqueous NaCl solution (30 mL).
The rich washed organic layer was concentrated to ˜50 mL at <40° C. under vacuum (˜25" of Hg) and heptane (˜100 mL) was added. The remaining MTBE was exchanged for heptane under vacuum and more heptane was added to a final volume of ˜150 mL (˜14 mL/g input). The heptane solution was cooled from 35° C. to ambient temperature to initiate crystallization of the product. The crystal slurry was stirred at ambient temperature for several hours. The crystal slurry was filtered, washed with cold (˜50° C.) heptane and dried under vacuum at ambient temperature to afford title compound as a white crystalline solid (10.5 g, ˜78M % as is).
To neat Example 2 compound (4.0 g, 14.2 mmol) was added neat benzyl amine (4.65 mL, 42.6 mmol, 3 equiv.) under nitrogen and the reaction mixture was heated at 100° C. to 110° C. until the GC area % ratio of input to output was <0.5 by the in-process GC method described in Example 1. The reaction mixture was worked up after 16 hours.
The reaction mixture was diluted with MTBE (˜80 mL) and was extracted successively with Dl water (3×40 mL), 1M aqueous NaH2 PO4 (40 mL, pH 5 buffer) and 3% (w/v) aqueous NaCl solution (40 mL).
The rich washed organic was concentrated to afford title compound as a clear oil (4.0 g, ˜92M % as is).
A. Preparation of Methanolic Solution of 2-Amino-3,3-dimethoxy-N-pentylpropanamide
Example 3 compound (37.5 g, 121.6 mmol) was dissolved in methanol (150 mL) and the solution was transferred into a Buchi hydrogenator. The apparatus was purged with nitrogen. About 5.3 g of Perlman catalyst 20% Pd(OH)2 -50.8% H2 O! were added and the apparatus was purged with hydrogen. The hydrogenolysis was conducted at 40° C. (jacket temperature) and at 25 psi pressure of hydrogen. The progress of the reaction was followed by the in-process GC method described in Example 1. The reaction was judged to be complete when the GC area % ratio of input to output was <0.1. The hydrogenolysis was stopped after four hours by purging the apparatus with nitrogen.
The reaction mixture was filtered to remove the catalyst. The catalyst was rinsed with MeOH (˜2×20 mL). The methanolic solution containing title compound (theoretical yield ˜26.5 g) was concentrated under vacuum at <40° C. to a volume of ˜60 mL (range 2 to 2.5 mL solution per gram of theoretical output of title compound).
B. Preparation of 2-Amino-3,3-dimethoxy-N-pentylpropanamide, oxalate (1:1)
Solid oxalic acid•2 H2 O (16.8 g, 133.7 mmol, 1.1 equiv.) was added to the Part A methanolic solution at ambient temperature and the agitation was continued to dissolve the acid. Ethyl acetate (˜100 mL) and MTBE (˜150 mL) were added and the solution was seeded to initiate crystallization of title compound (1:1 salt). Within 0.5 hour, the slurry became thick. Additional MTBE (˜250 mL) was added at ambient temperature over ˜2 hours.
The crystal slurry was stirred at ambient temperature for about 12 hours. The slurry was filtered, washed with MTBE (2×50 mL) and dried in vacuo at 30° C. to 35° C. to afford 33.1 g (88.2%) of title product having an HPLC determined H1 of 99.7.
A. 1S-(1α,2α,3α,4α)!-2- (3-Carboxy-7-oxabicyclo 2.2.1!hept-2-yl)methyl!benzenepropanoic acid chloride
The Vilsmeier reagent (chloromethylene)-dimethyl ammonium chloride! (5.83 g, 45.55 mmol) was charged to an oven-dried, nitrogen inerted round bottom flask. 1S-(1α,2α,3α,4α)!-2- (3-Carboxy-7-oxabicyclo- 2.2.1!hept-2-yl)methyl!benzenepropanoic acid (9.69 g, 30.44 mmol) was added along with dry toluene (70 mL, KF <0.05). The solution was agitated at room temperature until the HPLC area % ratio of BMS-191867-01 to the corresponding methyl ester was <2% (reaction time 1 hr) (note 1).
B. 1S-(exo,exo)!-2- 3- 2,2-Dimethoxy-1- (pentylamino)carbonyl!ethyl!amino!carbonyl!-7-oxabicyclo- 2.2.1!hept-2-yl!methyl!benzenepropanoic acid, methyl ester
Crude Part A compound (7.95 g, 36.47 mmol as is) was diluted in 270 mL EtOAc and cooled to 0°-10° C. To this, 60 mL DI water and 145 mL of 1 N NaHCO3 were added.
With vigorous agitation, the acid chloride solution was added to the biphasic Example 4 compound/NaHCO3 /EtOAc solution over 2.5 hr at 0°-10° C.
After addition, the reaction mixture was allowed to warm to ambient temperature.
The reaction mixture was heated to 45°-50° C. to achieve two clear phases. The lower spent aqueous phase was separated and the upper rich organic phase was washed with 1 N aqueous NaHCO3 (60 mL) followed by Dl water (2×60 mL). During work-up, the temperature was maintained at 45°-50° C. to prevent the product from crystallizing out.
The rich organic layer was cooled to 25° C. Product crystallization occurred before reaching 25° C. When the product slurry reached 25° C., 540 mL of n-heptane was added. The product cake was filtered and washed with 90 mL of n-heptane-EtOAc (75:25). The cake was dried in a vacuum oven at 40°-45° C. to afford 13.7 g (86.8 M % as is, Lab Hl 98.6 for the combined diastereomers) of title compound as a white crystalline solid.
Notes
1) HPLC method:
Column: Novapak phenyl, 3.9×150 mm; Flow rate: 1 mL/min; Detection: 215 nm
Mobile phase: Solvent A: 75% KH2 PO4 (0.02M, pH 4.5 with H3 PO4)+25% CH3 CN
Solvent B: 40% Dl water+60% CH3 CN
Gradient program:
______________________________________ Time (min) Solvent A Solvent B ______________________________________ 0 100 0 10 100 0 40 0 100 (linear gradient) 60 0 100 ______________________________________
Example 5 compound (20.72 g, 40 mmol) was slurried in 1,2-dimethoxyethane (280 mL) under N2 and heated to 38° C. Trimethylsilyl trifluoromethane-sulfonate (TMSOTf) (11.5 mL, 60 mmol; 1.5 equiv.) was added. The solid quickly dissolved and the reaction was stirred until done by HPLC (used 2 additional charges of TMSOTf totalling 1.6 mL, 8 mmol), typically 2 h. A mixture of four oxazolines was obtained. The reaction mixture was cooled to -13° C. and a solution of 25 wt. % NaOME/MeOH (26.3 mL, 115 mmol) was added to it rapidly keeping the temperature below 1° C. The reaction was typically over after 1 h of the addition of the base. The slurry was quenched with 10% HCl (43 mL) and then water (25 mL) was added to dissolve the salts. The solution was warmed to 45° C. and treated with water (215 mL) to crystallize the product. The solid was collected by filtration and washed twice with 1:2 DME/water. Title compound was obtained as an off-white solid in 92% weight yield with a lab HPLC HI of 99.
Example 5 compound (15 g, 28.92 mmol) was slurried in anhydrous methyl acetate under N2 and cooled to 0C. Chlorosulfonic acid (4.04 ml, 60.78 mmol, 2.1 eq.) was added. The solid quickly dissolved and the reaction was stirred for 2 h. A mixture of four oxazolines was obtained. This colorless solution was added dropwise by cannulation over 55 min. to a 0° C. solution of 1M potassium t-butoxide/t-butanol (144.6 ml, 144.6 mmol, 5.0 eq.) and anhydrous methyl acetate (52.5 ml). The reaction was done by the end of the addition. The slurry was quenched with 1 M HCl until neutral (24 ml), and then water (150 ml) was added to dissolve the salts. The water layer was separated. The organic layer was washed again with water (2×150 ml). The combined aqueous washes were extracted once with methyl acetate (150 ml). This second extract was washed once with water (50 ml). The organic extracts were combined, concentrated, and exchanged into ethanol. 1/15th of this solution was removed for another experiment. The remaining volume was adjusted to 140 ml. The solution was warmed to reflux and treated with water (185 ml) until cloudy to crystallize the product. The solid was collected by filtration and washed twice with cold 20% ethanol/water. Title compound (11.55 g) was obtained as an off-white solid in 94.1% weight yield with 98.4% HI.
Claims (22)
1. A method for preparing a compound of the structure ##STR36## wherein R is alkyl, aryl, arylalkyl or cycloalkyl and R1 is alkyl, arylalkyl or cycloalkyl, which comprises providing a compound of the structure ##STR37## wherein R2 is aryl or arylalkyl, and subjecting the above compound to hydrogenolysis to form a compound of the structure ##STR38##
2. The method as defined in claim 1 wherein R1 is CH3 and R is n-pentyl.
3. The method as defined in claim 1 wherein the hydrogenolysis is carried out by treatent with hydrogen in the presence of hydrogenolysis catalyst.
4. The method as defined in claim 1 wherein the starting compound ##STR39## is prepared by subjecting a compound of the structure ##STR40## to an amination reaction by reacting with an amine of the structure
R.sup.2 --NH.sub.2.
5. The method as defined in claim 4 wherein R1 is alkyl, R2 is arylalkyl, R is alkyl, and Hal is Br.
6. The method as defined in claim 4 wherein the compound of the structure ##STR41## is prepared by subjecting a compound of the structure ##STR42## to an amidation reaction by reacting with an amine of the structure
H.sub.2 N--R.
7. The method as defined in claim 6 wherein the compound of the structure ##STR43## wherein R1 is alkyl, is prepared by subjecting a compound of the structure ##STR44## to a halohydrin reaction by reacting with a halogenating agent and an alcohol R1 OH.
8. The method as defined in claim 6 wherein the halohydrin reaction is carried out by reacting the compound of the structure ##STR45## with N-bromosuccinimide and methanol, wherein R1 is alkyl.
9. A method for preparing a compound of the structure ##STR46## wherein R is alkyl, aryl, arylalkyl or cycloalkyl and R1 is alkyl, arylalkyl or cycloalkyl; which comprises reacting an acid chloride of the structure ##STR47## and a compound of the structure ##STR48## wherein R is alkyl, aryl, arylalkyl of cycloalkyl and R1 is alkyl, arylalkyl or cycloalkyl; in acoupling reaction to form a compound of the structure ##STR49##
10. The method as defined in claim 9 wherein the coupling reaction is a Schotten-Baumann coupling carried out in the presence of a base at a temperature within the range from about -15° to about 20° C.
11. A method for preparing a compound of the structure ##STR50## which comprises providing a starting compound of the structure ##STR51## wherein R is alkyl, aryl, arylalkyl or cycloalkyl and R1 is alkyl, aryl, arylalkyl or cycloalkyl, treating the above compound with a cyclizing agent to form a mixture of isomers of the structure ##STR52## and subjecting the above isomers to an elimination reaction to form the thromboxane receptor antagonist.
12. The method as defined in claim 11 wherein cyclization is achieved by reacting the starting compound with trimethylsilyl trifluoromethane sulfonate.
13. The method as defined in claim 11 wherein the elimination reaction is achieved by reacting the mixture of isomers with an organic base which is an alkali metal alkoxide.
14. The method as defined in claim 12 wherein the cyclization is carried out at a temperature within the range from about 15° to about 50° C.
15. The method as defined in claim 11 wherein R is n-pentyl and alkyl is CH3.
16. The method as defined in claim 11 wherein cyclization is achieved by reacting the starting material with a halosulfonic acid.
17. The method as defined in claim 16 wherein the halosulfonic acid is chlorosulfonic acid, bromosulfonic acid or fluorosulfonic acid.
18. The method as defined in claim 16 wherein the halosulfonic acid is chlorosulfonic acid.
19. The method as defined in claim 16 wherein the elimination reaction is achieved by reacting the mixture of isomers with potassium t-butoxide/butanol.
20. A compound having the structure ##STR53## wherein R is alkyl, aryl, arylalkyl or cycloalkyl; R1 is alkyl, arylalkyl or cycloalkyl;
R2 is aryl or arylalkyl;
R5 is amino, halogen, R2 NH, alkyl, aryl, arylalkyl or cycloalkyl.
21. The compound as defined in claim 20 having the structure ##STR54##
22. A compound as defined in claim 20 having the structure ##STR55##
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/828,460 USH1737H (en) | 1997-03-28 | 1997-03-28 | 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/828,460 USH1737H (en) | 1997-03-28 | 1997-03-28 | 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same |
Publications (1)
Publication Number | Publication Date |
---|---|
USH1737H true USH1737H (en) | 1998-06-02 |
Family
ID=25251869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/828,460 Abandoned USH1737H (en) | 1997-03-28 | 1997-03-28 | 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same |
Country Status (1)
Country | Link |
---|---|
US (1) | USH1737H (en) |
-
1997
- 1997-03-28 US US08/828,460 patent/USH1737H/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5594153A (en) | Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors | |
BG64823B1 (en) | Method for the preparation of citalopram | |
AU2004287416B2 (en) | CCR-2 antagonist salt | |
JPH07215921A (en) | Production of pest control agent and intermediate | |
CA2543250C (en) | Process for the preparation of ccr-2 antagonist | |
JP2002544207A (en) | 2,2-Dimethyl-1,3-dioxane intermediate salt and method for producing the same | |
USH1737H (en) | 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same | |
JPWO2006070671A1 (en) | 12-substituted mutilin derivatives | |
US5618949A (en) | Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds | |
AU664559B2 (en) | Synthesis of optically active lactones from L-aspartic acid and intermediates | |
KR20010042750A (en) | Method for producing enantiomer-free n-methyl-n-[(1s)-1-phenyl-2-((3s)-3-hydroxypyrrolidine-1-yl)ethyl]-2,2-diphenyl acetamide | |
KR870000323B1 (en) | Process for preparing 6-(amino methyl)penicillanic acid 1,1 dioxide esters | |
US5436347A (en) | Benzaldehyde intermediates useful in the preparation of 7-oxabicycloheptane carboxylic acid prostaglandin analog anti-thrombotic and anti-vasospastic compounds and method for preparing same | |
JP2001521498A (en) | Method for producing O- (3-amino-2-hydroxy-propyl) -hydroxymic acid halide | |
US6252082B1 (en) | Pyridone derivatives, their preparation and their use as synthesis intermediates | |
KR100189044B1 (en) | Process and intermediate for certain bis-aza-bicyclic anxiolytic agents | |
JP4181233B2 (en) | Method for producing pyrrolidine-2,4-dione derivative | |
US20040236118A1 (en) | Pyrrolidine derivatives and method of synthesizing these | |
JP4524845B2 (en) | Method for producing optically active allyl alcohol derivative having amino group, and optically active compound | |
JP2003514908A (en) | Methods and intermediates directed to tetrahydro- [1,8] -naphthyridine | |
KR100466797B1 (en) | Benzoazepin derivatives and process for production thereof using indium | |
KR20020038466A (en) | A process for the preparation of carbostyryl derivatives | |
KR100424393B1 (en) | Process for the preparation of oxiracetam | |
US4461728A (en) | Preparation of 4-phenyl-1,3-benzodiazepins | |
US20020019532A1 (en) | Process for the synthesis of (2S)-phenyl-3-piperidone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SWAMINATHAN, SHANKAR;SHER, PHILIP M.;SINGH, AMBARISH;AND OTHERS;REEL/FRAME:008487/0763;SIGNING DATES FROM 19970324 TO 19970326 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |